The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Sotyktu is not approved to treat rheumatoid arthritis. Adverse Reactions. The safety of Sotytku was assessed in 2 placebo- and active-controlled studies, PSO-1 and PSO-2, ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of its plaque psoriasis drug Sotyktu for the treatment of adults with active ...

Johnson & Johnson JNJ announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. "Today ...

Sotyktu (deucravacitinib) is a brand-name drug that’s prescribed for moderate to severe plaque psoriasis in certain adults. Sotyktu comes as an oral tablet that’s typically taken once per day.

Bristol Myers Squibb today announced new three-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients with moderate-to-severe plaque psoriasis. These ...

Sotyktu can provide appropriate patients with the chance of clearer skin. In two studies of people with moderate to severe plaque psoriasis including 1,684 adults, ...

Sotyktu helped more people have a clearer scalp compared to apremilast, with 70% of people having a clear or almost clear scalp at 16 weeks vs. 39% of people taking apremilast.

Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call ...

PRINCETON, N.J., February 16, 2025--New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis ...